To investigate the role of palonosetron in enhanced recovery after surgery (ERAS), and to provide a better choice for perioperative clinical patients.

A prospective, randomized study was carried out, enrolling one hundred and twenty patients undergoing laparoscopic colorectal surgery from September 2015 to February 2016, who were randomly divided into three groups with 40 cases in each group. All patients were treated with postoperative intravenous analgesia (PCIA) in the same formulation. Group A (control group) were given i. v 6 mg bolustropisetron 1 hour before the end of the surgery; Group B i. v 0.25 mg boluspalonosetron; Group C i. v 0.25 mg bolus palonosetron, then added intravenous palonosetron 0.25 mg/72 h. The incidence of postoperative nausea and vomiting (PONV), complication in PCIA except PONV, ambulation after surgery, and hospital-stay days were recorded.

The incidence of postoperative nausea and vomiting between Group B and Group A had no significant difference. Compared with Group A and Group B, the incidence of postoperative 24 h PONV in Group C was significantly different (χ²=5.165, 5.165, P=0.023, 0.023). The incidence of complication in PCIA except PONV between Group C and Group B, and Group C and Group A had significant differences after 24 h (χ²=4.500, 6.275, P=0.033, 0.012). Ambulation after surgery and the discharging days after surgery in Group C had significant differences compared to Group A and B (t=3.718, 2.975, P<0.001, 0.004; t=6.650, 5.440, both P<0.001).

Palonosetron continued injecting can more effectively reduce the incidence of postoperative nausea and vomiting, and improve the quality of rehabilitation.